1) Cetuximab(C225)
西妥昔单抗(C225)
2) Cetuximab
西妥昔单抗
1.
Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck;
西妥昔单抗联合化疗或放疗治疗晚期头颈鳞癌的疗效评价(英文)
2.
Effects of Cetuximab Combined Erlotinib on Proliferation of Human Hepatocellular Carcinoma Cell Lines HepG2 and Bel-7402;
西妥昔单抗联合厄洛替尼对人肝癌细胞的体外抑制作用
3.
Clinical observation of combination chemotherapy for metastatic colorectal cancer with Cetuximab;
西妥昔单抗联合化疗治疗转移性结直肠癌的临床观察
4) Rituximab
利妥昔单抗
1.
Effectiveness and pharmacoeconomic evaluation of rituximab for treatment of non-Hodgkin s lymphoma;
利妥昔单抗对于非霍奇金淋巴瘤的治疗及其药物经济学
2.
Rituximab in Combination with CHOP Scheme for Non-Hodgkin s Lymphoma: Evaluation of Clinical Efficacy;
利妥昔单抗联合CHOP方案治疗NHL的临床疗效评价
3.
Expression of CD16ζ in NK Cells of B-cell Non-Hodgkin s Lymphoma Patients and In Vitro Killing Effect of Rituximab Combined Lymphokine-activated Killer Cells on B-NHL Cells;
B-NHL患者NK细胞中CD16ζ表达及利妥昔单抗与LAK细胞的联合抗瘤作用
5) rituximab
利妥昔单克隆抗体
1.
In order to evaluate the effecicney of rituximab combined with fludarabine,cyclophosphamide and rituximab(FCR) regimen for chronic lymphocytic leukemia(CLL).
为了探讨利妥昔单克隆抗体联合氟达拉滨及环磷酰胺(FCR方案)治疗慢性淋巴细胞白血病(CLL)的疗效,采用FCR方案(2-6个疗程)治疗5例CLL患者,其中2例初治、3例复治。
2.
The aim of this study was to compare the efficacy of rituximab plus CHOP regimen and CHOP regimen on newly diagnosed patients with diffuse large B-cell lymphoma(DLBCL),and analyze their toxicities.
为比较利妥昔单克隆抗体联合标准CHOP方案与标准CHOP方案治疗初治CD20阳性的弥漫慢大B细胞淋巴瘤(DLBCL)患者的疗效和安全性,采用同期(2003年7月至2006年12月)非随机对照的前瞻性研究方法,将69例在我院住院的初治DLBCL患者分为R-CHOP组和CHOP组,其中CHOP组36例,R-CHOP组33例,比较两组的完全缓解率、生存期及不良反应情况。
6) Metuximab monoclonal antibody injection
碘[131I]美妥昔单抗注射液
1.
Objective To study the nursing highlights of iodine-[131I] Metuximab monoclonal antibody injection combined with hepatic artery embolization in treatment of primary liver cancer.
目的探讨碘[131I]美妥昔单抗注射液—利卡汀,联合肝动脉插管栓塞治疗原发性肝癌的护理要点。
补充资料：昔留昔零
1.象声词。形容风雨等的飘打声。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条